Yonsei Medical Journal

Yonsei Univ College Medicine (연세대학교의과대학)
권호 표지

Evaluation of HER2/neu Status by Real-Time Quantitative PCR in Breast Cancer

Kim, Young-Ree;Choi, Jong-Rak;Song, Kyung-Soon;Chong, Woo-Hee;Lee, Hy-De

  • Published : 20020600

⟨ Previous Next ⟩

Abstract

Over-expression of the human epidermal growth factor receptor-2 (HER2/neu) has been observed in many cancers, and is associated with a poor prognosis. Recent adjuvant treatment with anti-HER2 monoclonal antibodies in breast cancer has increased the demand for an evaluation of the HER2/neu status in breast cancer. The aim of this study was to investigate the HER2/neu status in breast cancer by a real-time quantitative polymerase chain reaction (PCR) method using LightCycler (Roche Diagnostics, Mannheim, Germany). DNA samples from the fresh tumor tissues of 27 patients with breast cancer were analyzed in parallel using immunohistochemistry (IHC) and the other prognostic parameters including estrogen receptor, progesterone receptor, cytokeratin, and DNA ploidy. Ten (37%) out of 27 cases tested were positive for HER2/neu, while 16 (73%) out of 22 tested positive through an IHC study. The correlation between the DNA aneuploidy and the positive results for HER2/neu were only observed using the real-time PCR method (p < 0.05). There was no significant correlation between the HER2/neu status and the S-phase fractions of the DNA ploidy or other parameters. This study demonstrated that there is marked discordance in the results for the HER2/neu status according to the various methods used. Real-time quantitative PCR for HER2/neu appears to be clinically useful due to its simplicity and ability to produce rapid results.

Keywords

References

  1. Am J Clin Pathol v.115 Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry O'Malley, F.P.;Parkes, R.;Latta, E.;Tjan, S.;Zadro, T.;Mueller, R.(et al.)
  2. Science v.235 Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene Slamon, D.J.;Clark, G.M.;Wong, S.G.;Levin, W.J.;Ullrich, A.;McGuire, W.L.
  3. Int J Cancer v.95 c-erbB-2 (HER2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast cancer patients Riou, G.;Mathieu, M.C.;Barrois, M.;Le Bihan, M.L.;Ahomadegbe, J.C.;Benard, J.(et al.)
  4. Anticancer Res v.21 Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study Meden, H.;Beneke, A.;Hesse, T.;Novophashenny, I.;Wischnewsky, M.
  5. Cancer Res v.61 Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2 Cuello, M.;Ettenberg, S.A.;Clark, A.S.;Keane, M.M.;Posner, R.H.;Nau, M.M.(et al.)
  6. Gan To Kagaku Ryoho v.28 Tumor markers in breast cancer Harada, Y.;Ohuchi, N.;Ishida, T.;Ohnuki, K.
  7. Pathologica v.93 Measurement of HER2/neu in breast cancer: which methodologic approach? Orvieto, E.;Dei, T.
  8. Eur J Cancer v.37 c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease Jukkola, A.;Bloigu, R.;Soini, Y.;Savolainen, E.R.;Holli, K.;Blanco, G.
  9. J Clin Oncol v.19 Comparison of methods of measuring HER2 in metastatic breast cancer patients treated with high-dose chemotherapy Harris, L.N.;Liotcheva, V.;Broadwater, G.;Ramirez, M.J.;Maimonis, P.;Anderson, S.(et al.)
  10. Arch Pathol Lab Med v.125 Fluorescence in situ hybridization and immunohistochemical assays for HER2/neu status determination: application to node-negative breast cancer Onody, P.;Bertrand, F.;Muzeau, F.;Bieche, I.;Lidereau, R.
  11. Cancer Res v.54 Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression Press, M.F.;Hung, G.;Godolphin, W.;Slamon, D.J.
  12. Clin Chem v.46 Influence of DNA target melting behavior on real-time quantification Wihelm, J.;Hahn, M.;Pingoud, A.
  13. Genes Chromosomes Cancer v.24 Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intesti-nal type of gastric cancer Vidgren, V.;Varis, A.;Kokkola, A.;Monni, O.;Puolakkainen, P.;Nordling, S.(et al.)
  14. Gene v.122 A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates Diviacco, S.;Norio, P.;Zentilin, L.;Menzo, S.;Clementi, M.;Biamonti, G.(et al.)